Atara Biotherapeutics Valuation

Q: What is the Fair Price of AT20 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

AT20 (€9.25) is trading below our estimate of [[fair value]] (€51.26)

Is AT20 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AT20 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AT20 (€9.25) is trading below our estimate of fair value (€51.26)

Significantly Below Fair Value: AT20 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AT20?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for AT20. This is calculated by dividing AT20's market cap by their current preferred multiple.
What is AT20's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

AT20 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	-0.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AT20's PS Ratio compare to its peers?

The above table shows the PS ratio for AT20 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.2x
HPHA Heidelberg Pharma	13.2x	16.6%	€118.4m
MDG1 Medigene	3.4x	16.1%	€24.1m
2INV 2invest	7.7x	n/a	€59.8m
CNW co.don	0.7x	n/a	€6.5m
AT20 Atara Biotherapeutics	0.8x	17.8%	€47.8m

Price-To-Sales vs Peers: AT20 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (7.8x).

Price to Earnings Ratio vs Industry

How does AT20's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.2%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: AT20 is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Biotechs industry average (9x).

Price to Sales Ratio vs Fair Ratio

What is AT20's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AT20 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.8x
Fair PS Ratio	0.3x

Price-To-Sales vs Fair Ratio: AT20 is expensive based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.